Quarterly report pursuant to Section 13 or 15(d)

Licenses Acquired - Additional Information (Detail)

v3.3.0.814
Licenses Acquired - Additional Information (Detail) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Jul. 16, 2015
Apr. 28, 2015
Apr. 02, 2015
Sep. 30, 2015
Jun. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Payments to Acquire Intangible Assets             $ 1,250,000 $ 0
Stock Issued During Period, Value, Issued for Services             1,000 4,000
Research And Development Expense       $ 9,073,000   $ 1,609,000 13,172,000 $ 8,473,000
Payments to Acquire in Process Research and Development             $ 1,600,000  
Share Price       $ 9.49     $ 9.49  
Scientific Advisory Board [Member]                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Stock Issued During Period, Shares, Issued for Services             1,500,000  
Stock Issued During Period, Value, Issued for Services             $ 200,000  
National Institutes of Health [Member]                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Payment of Upfront Milestone Fees $ 700,000              
New Zealand Pharmaceuticals Ltd [Member]                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Reimbursement Revenue 600,000              
Dana Farber Cancer Institute [Member]                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Marketability Percentage Of Invested Capital             44.80%  
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent             30.00%  
Research And Development Expense       $ 600,000        
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares             500,000  
Share Price       $ 0.065     $ 0.065  
Dana Farber Cancer Institute [Member] | Research and Development Expense [Member]                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Research And Development Expense             $ 32,500  
Escala Therapeutics, Inc [Member]                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Research And Development Expense       $ 1,300,000     1,300,000  
Payment of Upfront Fees 1,300,000              
Reimbursement Revenue $ 1,300,000              
Collaboration Agreement with TGTX [Member]                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Payments for Fees             500,000  
Collaboration Agreement with TGTX [Member] | NeuPharma [Member]                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Payments for Fees             25,000  
Collaboration Agreement with TGTX [Member] | TG Therapeutics, Inc [Member]                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Payments for Fees             500,000  
Agreement With City Of Hope [Member] | Mustang Bio, Inc [Member]                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Payments to Acquire in Process Research and Development             $ 2,000,000  
Restricted Stock Purchase Agreement [Member] | Dana Farber Cancer Institute [Member]                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage             25.00%  
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period             48 months  
Chief Executive Officer [Member]                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Stock Issued During Period, Shares, Issued for Services             1  
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights             grant vests 50% in four annual equal tranches of 12.5%, with the remaining 50% vesting upon the achievement of certain performance goals.  
Coronado SO [Member]                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Payments for Fees             $ 500,000  
Independent Consultant [Member]                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Share Price       $ 4.39     $ 4.39  
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate             83.00%  
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate             1.54%  
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term             5 years  
IV Tramadol [Member]                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Marketability Percentage Of Invested Capital             44.80%  
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent             30.00%  
Share Price       $ 0.146     $ 0.146  
Checkpoint Therapeutics, Inc [Member]                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Research And Development Expense       $ 2,700,000     $ 2,700,000  
Checkpoint Therapeutics, Inc [Member] | Dana Farber Cancer Institute [Member]                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Stock Issued During Period, Shares, Purchase of Assets             136,803  
Stock Issued During Period, Value, Purchase of Assets             $ 10.9  
Research And Development Expense       600,000     $ 600,000  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares             1,368,030  
Helocyte Biosciences Inc [Member]                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Research And Development Expense       200,000     $ 200,000  
Licensing Agreements [Member]                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Payments to Acquire Intangible Assets   $ 50,000 $ 150,000          
Licensing Agreements [Member] | NeuPharma [Member]                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Payments for Fees             $ 1,000,000  
Licensing Agreements [Member] | City Of Hope [Member]                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Marketability Percentage Of Invested Capital             83.00%  
Payments for Fees             $ 2,000,000  
Stock Issued During Period, Shares, Other             1,000,000  
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent             30.00%  
Research And Development Expense       $ 100,000     $ 100,000  
Share Price       $ 0.147     $ 0.147  
Stock Issued During Period, Value, Other             $ 100,000  
Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Shares Issued     500,000          
Licensing Agreements [Member] | Dana Farber Cancer Institute [Member]                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Payments for Fees             $ 1,000,000  
Licensing Agreements [Member] | Coronado SO [Member]                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Marketability Percentage Of Invested Capital             44.80%  
Payments for Fees             $ 900,000  
Stock Issued During Period, Shares, Other             150,000  
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent             30.00%  
Share Price       $ 1.19     $ 1.19  
Stock Issued During Period, Value, Other             $ 200,000  
Licensing Agreements [Member] | IV Tramadol [Member]                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Payments to Acquire Intangible Assets             1,000,000  
Payments for Fees             2,000,000  
Avenue Therapeutics, Inc. [Member]                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Stock Issued During Period, Value, Issued for Services       $ 14,700     37,600  
Avenue Therapeutics, Inc. [Member] | Chief Executive Officer [Member]                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Stock Issued During Period, Shares, Issued for Services         1,000,000      
Avenue Therapeutics, Inc. [Member] | Consultants [Member]                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Stock Issued During Period, Shares, Issued for Services       150,000 150,000      
Stock Issued During Period, Value, Issued for Services       $ 15,000     $ 37,600